Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause

Update Il y a 4 ans
Reference: NCT00195546

Woman Man

Extract

Primary: To assess the efficacy and safety of DVS-233 SR compared with placebo for treatment of vasomotor symptoms (VMS) associated with menopause and to compare the bleeding incidence of DVS-233 SR and tibolone. Secondary: To assess the effects of DVS-233 SR and tibolone on changes from baseline in weight, breast pain, and health outcomes indicators.


Inclusion criteria

  • Menopause


Links